GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma

Sun Yat-sen University

Status and phase

Unknown

Phase 2

Conditions

Extranodal NK/T-cell Lymphoma, Nasal Type

Treatments

Drug: Gemcitabine

Drug: Pegaspargase

Drug: Dexamethasone

Drug: High dose of methotrexate

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01991158

B2013-030-01

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of High dose of Methotrexate combined with gemcitabine, pegaspargase and dexamethasone (GAD-M regimen) as first-line treatment in patients with de novo extranodal NK/T cell lymphoma.

Full description

Studies have shown that effects of P glycoprotein mediated chemotherapy resistance reduce the therapeutic efficacy of anthracycline-based chemotherapy of NK/T cell lymphoma, and agents like pegaspargase and large doses of Methotrexate is not affected by the P glycoprotein. A number of reports suggest that gemcitabine combined with other chemotherapy drugs has good application prospect in the treatment of lymphomas. Dexamethasone is used in combination with other agents for the treatment of lymphomas which may be implicated in the development or growth of some cancers. So we explored to evaluate the efficacy and safety of High dose of methotrexate combined with gemcitabine, pegaspargase and dexamethasone (GAD-M regimen) as first-line treatment in patients with untreated extranodal NK/T cell lymphoma.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologic diagnosis of NK/T Cell Lymphoma;
Age:18-80 years;
Weight：Male：67±20Kg（47-87Kg），Female：55±20Kg（35-75Kg）
Eastern Cooperative Oncology Group (ECOG) status 0-3, Estimated survival time > 3 months;
No history of other malignancies; No other current tumors；
Normal haematological, liver and renal function (WBC count≥3.5×109/L, Hemoglobin≥100g/L, platelet count≥90×109/L, bilirubin<1.5×ULN, Alanine transaminase (ALT) and Aspartate Aminotransferase (AST)<2.5×ULN, serum creatinine<1.5×ULN), normal coagulation function and cardiac function;
Clinical staging I-IV；
No previous treatments including chemotherapy, radiotherapy, targeted therapy or stem cell transplantation;
Appreciable and measurable lesions, clinical assessment >2cm，CT or MRI >1.5cm;
No other serious diseases which conflict with the treatment in the present trial;
No concurrent treatments that conflict with the treatments in the present trial(including steroid drugs);
Voluntary participation and signed the informed consent.

Exclusion criteria

The patients had the conditions below: clinically significant ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), symptomatic coronary artery heart disease requiring medication;
The patients suffered from organ transplant
The patients participated in other clinical trials within the 30 days before enrollment or who are participating in other clinical studies;
The patients with active bleeding or new thrombotic disease, who are taking anticoagulant drugs or with a history of bleeding tendencies，who with active infection;
The patients suffered before surgery less than four weeks, or after less than six weeks;
The patients with abnormal liver function (total bilirubin> 1.5 times the normal value, ALT / AST> 2.5 times normal), abnormal renal function (serum creatinine> 1.5 times normal), blood abnormalities (absolute neutrophil count <1.5 × 109 / L, platelets <80 × 109 / L, hemoglobin <90g /L) ;
The patients with mentally ill / unable to obtain informed consent;
The patients with drug addiction, alcohol abuse which affects the long-term evaluation of test results;
The patients in pregnancy, lactation and women of childbearing age who do not want to take contraceptive measures subjects;
Clinical and laboratory support brain metastases;
The patients with a history of allergy or adverse reaction(s) to test drug;
The patients not suitable to participate in the investigator judged by researchers.